Preservation Bio

Current Stage: Pre-Clinical Indication: Ex Vivo Platelet Additive Preservation Bio, a subsidiary of Orange Grove Bio (“OGB”), is at the forefront of developing a revolutionary ex vivo platelet additive designed to transform the shelf life and quality of donated platelets for transfusions. Built upon discoveries from the University of Cincinnati and Cincinnati Children’s Hospital Medical Center, Preservation Bio was formed to address the global platelet shortage caused by decreasing donations and supply waste due to the short shelf life of donated platelets that must currently be stored at room temperature. The company has secured the rights to this cutting-edge technology directly from renowned academic investigators, Dr. Jose Cancelas and Dr. Yi Zheng, who serve as the scientific co-founders of Preservation Bio and are widely regarded as leading authorities in the field of transfusion medicine. Dr. Cancelas, a distinguished expert in transfusion medicine, and Dr. Zheng, an expert in RhoA biochemistry, led the pioneering research efforts at the University of Cincinnati and Cincinnati Children’s Hospital Medical Center, laying the groundwork for Preservation Bio’s innovative platelet storage solution. They have played a pivotal role in advancing Preservation Bio’s mission to improve patient outcomes and revolutionize the platelet donation storage process. The company’s ex vivo additive protects platelets from the damage normally caused by cold temperatures,allowing them to be stored in the refrigerator. This represents a commercial opportunity that will benefit both hospitals and cancer clinics and their patients. Preservation Bio’s product is designed to be added to bags of donated platelets, allowing them to be refrigerated and extending their shelf life from the current 5-7 days up to 14 days or possibly longer. This could significantly reduce the number of platelets that are discarded each year due to expiration (currently 10-15%).